Copenhagen, 2016-04-19 08:23 CEST (GLOBE NEWSWIRE) -- Exiqon A/S (Nasdaq Copenhagen: “EXQ”) today announced on behalf of QIAGEN N.V the submission of a takeover offer to buy the entire share capital of Exiqon A/S. The price offered is DKK 18.00 per share of nominal DKK 1.00. The offer is valid until 18 May 2016 at 23.59 (CET). Please find enclosed a copy of the submitted Offer Document, Offer Advertisement and Acceptance Form.
In accordance with Section 23 of the Takeover Order (bekendtgørelse om overtagelsestilbud no. 562/2014), the Supervisory Board of Exiqon A/S has prepared a statement about the takeover offer. The Supervisory Board recommends the shareholders of Exiqon A/S to accept the takeover offer submitted by QIAGEN N.V. Please find enclosed a copy of the statement prepared by the Supervisory Board.
Additional information
Erik Walldén, Chairman of the Board of Directors, Mobile: +46 70 225 2270
About Exiqon
At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon’s research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visit www.exiqon.com
